Research Library — Page 61 | Reta Compare
3563 research articles. Page 61 of 143.
Articles
- Eli Lilly's Retatrutide: Insights Ahead of Upcoming Trial Results
- Concerns Over Fake Weight-Loss Drugs Amid Retatrutide's Rise in Popularity
- New Insights into Retatrutide: Implications for Obesity Management
- Exploring the Potential of Retatrutide for Effective Weight Management
- Exploring Retatrutide: Promising Weight Loss with Uncertain Safety Profile
- U.K. Regulators Target Illicit Production of Retatrutide and Tirzepatide
- Exploring the Implications of Retatrutide in Peptide Research
- Exploring the Early Access to Retatrutide Among Bodybuilders and Fitness Influencers
- Understanding Retatrutide in the Context of Mounjaro and Wegovy Price Changes
- Exploring the Potential of Retatrutide in Weight Loss Management
- Exploring the Role of Retatrutide in Weight Loss Among GLP-1 Receptor Agonists
- Exploring the Efficacy of Retatrutide for Weight Loss in Adults with Obesity
- Retatrutide Demonstrates Efficacy in Reducing UACR and Enhancing eGFR in Obesity
- Exploring Retatrutide: Implications for Weight Loss and Clinical Applications
- Retatrutide Shows Promise in Mitigating Cancer Progression Linked to Obesity
- Exploring the Rapid Fat Loss Effects of Retatrutide and Associated Risks
- Eli Lilly to Present Early Data on Retatrutide, a Next-Generation Weight Loss Drug
- Retatrutide Demonstrates Superior Weight Loss Compared to Ozempic in Recent Study
- Retatrutide Demonstrates Significant Weight Loss Potential in Recent Studies
- Eli Lilly's Retatrutide Study Receives CDSCO Approval for Protocol Amendments
- Exploring Retatrutide: A New Approach in Weight Loss Treatment
- Retatrutide: Insights on FDA Biologics Designation and Market Strategy
- Retatrutide Shows Promising Effects on Lipid and Cardiovascular Risk Factors in Phase II Study
- Exploring Retatrutide's Triple Agonism at GLP-1R, GIPR, and GCGR
- Retatrutide's Role in Treating Metabolic Dysfunction-Associated Steatotic Liver Disease